Actionable news
All posts from Actionable news
Actionable news in ARRY: Array BioPharma Inc.,

Array BioPharma’s New FDA Submissions Enough to Excite Investors?

Array BioPharma Inc. (NASDAQ: ARRY) saw its shares were up handily in Wednesday’s premarket after the firm announced a critical submission to the U.S. Food and Drug Administration (FDA). Specifically, Array is submitting two New Drug Applications (NDAs) to support the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

One real positive surrounding these submissions are that they are supported by data from the pivotal Phase 3 Columbus study. Ultimately this...